Once again, an unforgettable date in our calendars that the MedSIR team couldn’t miss out: The IV Foro en Oncología Médica en 3 Días (OM3d)! Year by year, the annual Foro is turning into one of the most important oncology congresses, where the brightest minds in this field come to present the latest updates in clinical research.

This year the event was celebrated at the beginning of May in Madrid and we could proudly say that we learned too many important things. First of all, the amazing presentation by Dr. Esther Holgado talking about innovation in the management of pain in cancer patients. She said: “we must understand the pain that may suffer our cancer patients. If a patient said that it hurts is because it really hurts”.
We had the opportunity to hear about the benefits of selecting and targeting the best biomarkers to effectively kill breast cancer cells, conducted by Dr. Aleix Prat and Dr. José Manuel Pérez García gave us a nice shoot about all the therapeutic strategies to defeat HER2-positive breast cancer tumors depending on the subtype and phenotypic characteristics.

From Dr. Antonio Llombart we understood the reason to find a good biomarker to choose between chemotherapy and hormone therapy in neoadjuvancy. And of course, a terrific presentation by Dr. Javiér Cortés very focused on the explanation of the best treatment options when treating HER2+ breast tumors.

What an amazing team-training experience, we keep the nice taste of learning from the greatest minds in Spanish oncology. See you all next year to keep learning how to bring new ideas to life, and how to improve our cancer patient’s quality of life.

​

​